Andreas Krekeler

This inventor holds 6 USPTO granted patents and 8 published patent applications, plus 1 CIPO patent and 5 EPO patents. Top assignees: Hexal Ag, Sandoz Ag. Active years: 2019-2021.

USPTO Granted Patents = 6 (Patent Applications = 8)

% Patents Active = 16.7

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 5 (Patent Applications = 17)

Average Co-Inventor Count = 1.6

ph-index = 1

Forward Citations = 2(Granted Patents)

Company Filing History:

Years Active: 2019-2021

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11123300 - Immediate release tablet of a benzothiophene compound (2021-09-21),

2. 11072605 - Crystalline brexpiprazole (2021-07-27),

3. 10668073 - Pharmaceutical composition containing 8-[(3R)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof (2020-06-02),

4. 10485799 - Pharmaceutical composition of vortioxetine hydrobromide comprising vortioxetine hydrobromide in a polyethylene oxide matrix (2019-11-26),

5. 10335443 - Orodispersible film (2019-07-02),

6. 10206880 - Solid dispersion comprising an orexin receptor antagonist (2019-02-19),

Title: Innovations of Andreas Krekeler

Introduction

Andreas Krekeler is a notable inventor based in Holzkirchen, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative drug formulations. With a total of six patents to his name, Krekeler's work focuses on improving the efficacy and delivery of medications.

Latest Patents

Krekeler's latest patents include an immediate release tablet of a benzothiophene compound. This invention discloses a tablet core that comprises at most 20% brexpiprazole relative to the total of the tablet core, along with at least one pharmaceutically acceptable excipient. The tablet core is made by direct compression, which enhances its release properties. Another significant patent involves crystalline brexpiprazole, characterized by a specific particle size distribution. This invention relates to a pharmaceutical composition that includes crystalline brexpiprazole, which is essential for the treatment or prevention of relapse in conditions such as schizophrenia, bipolar disorder, or depression.

Career Highlights

Throughout his career, Krekeler has worked with prominent companies in the pharmaceutical industry, including Hexal AG and Sandoz AG. His experience in these organizations has contributed to his expertise in drug formulation and development.

Collaborations

Krekeler has collaborated with notable professionals in his field, including Michael Sedlmayr and Dimitri Neumann. These collaborations have likely enriched his research and innovation efforts.

Conclusion

Andreas Krekeler's contributions to pharmaceutical innovations demonstrate his commitment to advancing medical science. His patents reflect a deep understanding of drug formulation, which has the potential to improve patient outcomes significantly.